Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.19.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 2,018 $ 444
Operating expenses:    
Research and development (related party of $954 and $877), net of grant income of $37 and $44 5,474 3,986
General and administrative (related party of $1,051 and $942) 12,332 10,685
Total operating expenses 17,806 14,671
Operating loss (15,788) (14,227)
Other income (expense):    
Interest expense - related party (1,900) (1,915)
Interest income 75 15
Royalty income 16 19
Total other income (expense) (1,809) (1,881)
Consolidated net loss (17,597) (16,108)
Net loss attributable to noncontrolling interest 4 3
Net loss attributable to iBio, Inc. (17,593) (16,105)
Preferred stock dividends (260) (260)
Net loss available to iBio, Inc. (17,853) (16,365)
Comprehensive loss:    
Consolidated net loss (17,597) (16,108)
Other comprehensive loss - foreign currency translation adjustments (1) (1)
Comprehensive loss $ (17,598) $ (16,109)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.94) $ (1.54)
Weighted-average common shares outstanding - basic and diluted 18,926 10,631